Accretive Health
AH
AH was delisted on the 14th of March, 2014.
0 hedge funds and large institutions have $0 invested in Accretive Health in 2017 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 4 closing their positions.
100% less funds holding
Funds holding: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $6.52M → $0 (-$6.52M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$3.42M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$2.01M |
| 3 |
PA
Perceptive Advisors
New York
|
-$709K |
| 4 |
RMC
Regis Management Company
Menlo Park,
California
|
-$282K |
AH Hedge Fund Activity: Q1 2017 in Review
0 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Accretive Health (AH) for Q1 2017, worth a combined $0 — down 100% from $6.52M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AH and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Neuberger Berman Group, exiting entirely with an estimated $3.42M sold.
- 0 institutional investors held Accretive Health (AH) as of Q1 2017, down from 5 in Q4 2016.
- Funds reported $0 of Accretive Health stock for Q1 2017, down 100% quarter-over-quarter.
- 0 funds opened new Accretive Health positions in Q1 2017 and 4 closed out, a net change of -4 holders.
- The largest Accretive Health seller in Q1 2017 was Neuberger Berman Group, an estimated $3.42M sold.
Based on aggregated 13F filings for Q1 2017.